The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
What have clinical & immune analyses of MSCs revealed and what does it mean for resistant psoriasis?
Featured:
Su Mar Lwin
Christopher GriffithsDuring the 1st International Societies for Investigative Dermatology (ISID) meeting, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Su Mar Lwin, St John’s Institute of Dermatology, London, UK and Christopher Griffiths, University of Manchester, Manchester, UK and King’s College London, London, UK. We asked, What have clinical & immune analyses of MSCs revealed and what does it mean for resistant psoriasis?
What have clinical & immune analyses of MSCs revealed and what does it mean for resistant psoriasis?
In this video interview, Su Mar Lwin outlines the indications of stem cell therapy in resistant psoriasis, including its mode of action and the characteristics which make MSCs useful in this patient group.
Christopher Griffiths goes on to discuss two real life cases of patients who were treated with MSCs. The speakers outline the impacts of treatment in each case, highlighting patient-reported symptom outcomes and psoriasis area and severity index status. The immune cell response following MSC treatment is also discussed, with both speakers providing their insight into the application of MSCs and which patients may benefit most from infusion.